TAG:
laboratory testing
This Coronavirus Outbreak Will Change Lab Industry
By Robert Michel | From the Volume XXVII No. 5 – March 30, 2020 Issue
CEO SUMMARY: COVID-19 is causing a level of global disruption not seen since the influenza outbreak of 1918. This new infectious disease exposes flaws in the strategies and planning of public health officials and governments in the United States and abroad. In this country…
COVID-19 Patient? Northwell Has Mobile Phlebotomy App
By Joseph Burns | From the Volume XXVII No. 4 – March 9, 2020 Issue
>CEO SUMMARY: What better way to limit the spread of a deadly novel coronavirus than to allow patients who suspect they have the COVID-19 illness to use a mobile phone to book an appointment with a phlebotomist who makes house calls? Northwell Laboratories started this service in Novem…
New UnitedHealthcare Policy For Hospital Reference Tests
By Joseph Burns | From the Volume XXVII No. 4 – March 9, 2020 Issue
>CEO SUMMARY: Under a new policy UnitedHealthcare will start in May, hospital laboratories will no longer be allowed to bill for reference testing for members who are not hospital patients. The policy is likely to affect clinical lab testing for patients whose testing goes …
Be Careful Payers, You May Get What You Wish For!
By R. Lewis Dark | From the Volume XXVII No. 4 – March 9, 2020 Issue
Few clinical laboratory executives and pathologists would disagree with the assertion that both government and private payers would like to see the prices they pay for medical laboratory testing and the amount of money they spend reimbursing labs to stay flat or shrink from one year to the next. C…
Northwell Health Labs Produce Value-Added Outcomes, Growth
By Joseph Burns | From the Volume XXVII No. 3 – February 17, 2020 Issue
>CEO SUMMARY: In 2008, the administration at the Northwell Health system on Long Island considered selling its inpatient and outpatient laboratory services to a commercial laboratory company. In response, the leaders of the Northwell Health Laboratories proposed a plan to s…
Two Collaborations: LabCorp-Thermo Fisher, Roche-Illumina
By Joseph Burns | From the Volume XXVII No. 2 – January 27, 2020 Issue
In deals related to the pursuit of companion diagnostics, two lab companies announced collaboration deals with companies that manufacture gene-sequencing equipment. The deals were announced on consecutive days earlier this month. Financial terms were not disclosed. On Jan. 13, Ro…
NeoGenomics Spends $37M for Human Longevity’s Oncology Division
By Joseph Burns | From the Volume XXVII No. 2 – January 27, 2020 Issue
Once again, Neogenomics, Inc. is using an acquisition to build up its cancer-testing business. In a deal that closed on Jan. 10, the lab company acquired the Oncology Division of Human Longevity, based in San Diego. Neogenomics said it paid $37 million f…
33 Groups Cooperated to Get PAMA-Related LAB Act Passed
By Joseph Burns | From the Volume XXVII No. 2 – January 27, 2020 Issue
>CEO SUMMARY: At the end of 2019, the Laboratory Access for Beneficiaries (LAB) Act became law and addressed two of the three most onerous requirements in the Protecting Access to Medicare Act (PAMA) of 2014. It delays the data-reporting requirements under PAMA, an…
Any Hope for Relief from PAMA Medicare Price Cuts?
By R. Lewis Dark | From the Volume XXVII No. 2 – January 27, 2020 Issue
It is a notable and rare success for the clinical laboratory profession to convince the House and Senate to pass a law that is favorable to the interests of patients and the clinical laboratories that serve them. Yet that is what happened when Congress passed the Laboratory Access for Beneficiarie…
Labs Face New Challenges in New Year, New Decade
By R. Lewis Dark | From the Volume XXVII No. 1 – January 6, 2020 Issue
TYPICALLY, PEOPLE CELEBRATE THE ARRIVAL OF A NEW YEAR and a new decade with optimism. That should be just as true for clinical lab managers and pathologists. After all, medical laboratory testing is fundamental to how physicians diagnose disease, select the most appropriate therapies, and monitor the…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized